Cargando…

Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy

Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Weiwei, Liu, Chaoqun, Wang, Hui, Xu, Lijun, Zhou, Jueyu, Li, Sihua, Cheng, Yu, Zhou, Rui, Zhao, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508382/
https://www.ncbi.nlm.nih.gov/pubmed/36187919
http://dx.doi.org/10.1016/j.csbj.2022.09.017
_version_ 1784797005427507200
author Liu, Weiwei
Liu, Chaoqun
Wang, Hui
Xu, Lijun
Zhou, Jueyu
Li, Sihua
Cheng, Yu
Zhou, Rui
Zhao, Liang
author_facet Liu, Weiwei
Liu, Chaoqun
Wang, Hui
Xu, Lijun
Zhou, Jueyu
Li, Sihua
Cheng, Yu
Zhou, Rui
Zhao, Liang
author_sort Liu, Weiwei
collection PubMed
description Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs have been successfully applied in the treatment of different cancers, the low effectiveness rate has dramatically restrained the clinical application of ICI treatment. N6-methyladenosine (m6A) modification is the most common RNA methylation. Recent studies have pointed out that m6A epigenetic modification could improve the efficacy of ICI blockade treatment. Here, we briefly summarize the relevant mechanisms of tumour immunity, the clinical application of ICIs, the resistance to ICI treatment in cancers, and the m6A epigenetic modification and how it regulates the response to ICI treatment. We attempted to provide a potential strategy for cancer therapy by targeting m6A modification combined with ICI blockade treatment.
format Online
Article
Text
id pubmed-9508382
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Research Network of Computational and Structural Biotechnology
record_format MEDLINE/PubMed
spelling pubmed-95083822022-09-30 Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy Liu, Weiwei Liu, Chaoqun Wang, Hui Xu, Lijun Zhou, Jueyu Li, Sihua Cheng, Yu Zhou, Rui Zhao, Liang Comput Struct Biotechnol J Review Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs have been successfully applied in the treatment of different cancers, the low effectiveness rate has dramatically restrained the clinical application of ICI treatment. N6-methyladenosine (m6A) modification is the most common RNA methylation. Recent studies have pointed out that m6A epigenetic modification could improve the efficacy of ICI blockade treatment. Here, we briefly summarize the relevant mechanisms of tumour immunity, the clinical application of ICIs, the resistance to ICI treatment in cancers, and the m6A epigenetic modification and how it regulates the response to ICI treatment. We attempted to provide a potential strategy for cancer therapy by targeting m6A modification combined with ICI blockade treatment. Research Network of Computational and Structural Biotechnology 2022-09-15 /pmc/articles/PMC9508382/ /pubmed/36187919 http://dx.doi.org/10.1016/j.csbj.2022.09.017 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Liu, Weiwei
Liu, Chaoqun
Wang, Hui
Xu, Lijun
Zhou, Jueyu
Li, Sihua
Cheng, Yu
Zhou, Rui
Zhao, Liang
Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy
title Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy
title_full Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy
title_fullStr Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy
title_full_unstemmed Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy
title_short Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy
title_sort targeting n6-methyladenosine rna modification combined with immune checkpoint inhibitors: a new approach for cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508382/
https://www.ncbi.nlm.nih.gov/pubmed/36187919
http://dx.doi.org/10.1016/j.csbj.2022.09.017
work_keys_str_mv AT liuweiwei targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy
AT liuchaoqun targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy
AT wanghui targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy
AT xulijun targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy
AT zhoujueyu targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy
AT lisihua targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy
AT chengyu targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy
AT zhourui targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy
AT zhaoliang targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy